Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 14Gastrointestinal 5Thoracic 3Head & Neck 3Breast 3Dermatologic 2Sarcoma 1Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 2Mesothelioma 2Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Turcot syndrome 1Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Microsatellite Instability 1Mesothelioma, Malignant 1Mesothelin-positive Advanced Refractory Solid Tumors 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Advanced Solid Tumor 1

Interventions

pembrolizumab 8fludarabine 4Cyclophosphamide 4amatuximab 3Thiotepa 3Nivolumab 3Ipilimumab 3Hyperthermic Intraperitoneal Chemotherapy 3Filgrastim 3Carboplatin 3budigalimab 2belinostat 2SS1(dsFv)PE38 2Platinum 2Peripheral Blood Stem Cell Transplantation 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2venetoclax 1talazoparib 1sodium thiosulfate 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1obinutuzumab 1naptumomab estafenatox 1fludarabine phosphate 1epacadostat 1durvalumab 1bosutinib 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × fludarabine phosphate × Other solid neoplasm × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡